Mackenzie Financial Corp Buys 29,440 Shares of Abbott Laboratories $ABT

Mackenzie Financial Corp increased its position in Abbott Laboratories (NYSE:ABT) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,507,609 shares of the healthcare product maker’s stock after purchasing an additional 29,440 shares during the period. Mackenzie Financial Corp owned approximately 0.09% of Abbott Laboratories worth $201,929,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ABT. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. State Street Corp grew its holdings in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after purchasing an additional 689,517 shares during the last quarter. Capital International Investors increased its stake in Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the period. Geode Capital Management LLC raised its stake in shares of Abbott Laboratories by 3.8% during the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after acquiring an additional 1,390,554 shares during the last quarter. Finally, Norges Bank purchased a new position in Abbott Laboratories during the 2nd quarter valued at $3,026,180,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.8%

NYSE ABT opened at $110.60 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average price is $115.55 and its 200-day moving average price is $124.29. The stock has a market cap of $192.18 billion, a PE ratio of 29.73, a PEG ratio of 1.79 and a beta of 0.74. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the business posted $1.34 EPS. The business’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ABT. Leerink Partners lowered their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Piper Sandler cut their target price on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Evercore dropped their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $136.37.

Insider Transactions at Abbott Laboratories

In other news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last quarter. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.